Demonstrated 0 12 0 12 O
intolerance 13 24 13 24 O
or 25 27 25 27 O
inadequate 28 38 28 38 O
response 39 47 39 47 O
to 48 50 48 50 O
biologic 51 59 51 59 B-treatment
therapy 60 67 60 67 I-treatment
for 68 71 68 71 O
CD 72 74 72 74 B-chronic_disease

Diagnosis 0 9 75 84 O
of 10 12 85 87 O
CD 13 15 88 90 B-chronic_disease
for 16 19 91 94 O
at 20 22 95 97 O
least 23 28 98 103 O
3 29 30 104 105 B-lower_bound
months 31 37 106 112 I-lower_bound
prior 38 43 113 118 I-lower_bound
to 44 46 119 121 O
Baseline 47 55 122 130 O

Having 0 6 131 137 O
an 7 9 138 140 O
ostomy 10 16 141 147 B-treatment
or 17 19 148 150 I-treatment
ileoanal 20 28 151 159 I-treatment
pouch 29 34 160 165 I-treatment

Male 0 4 166 170 B-gender

Prior 0 5 171 176 O
exposure 6 14 177 185 O
to 15 17 186 188 O
p19 18 21 189 192 B-treatment
inhibitors 22 32 193 203 I-treatment
( 33 34 204 205 O
e.g. 34 38 205 209 O
, 38 39 209 210 O
risankizumab 40 52 211 223 B-treatment
) 52 53 223 224 O

Receipt 0 7 225 232 O
of 8 10 233 235 O
Crohn 11 16 236 241 B-chronic_disease
's 16 18 241 243 I-chronic_disease
disease 19 26 244 251 I-chronic_disease
approved 27 35 252 260 O
biologic 36 44 261 269 B-treatment
agents 45 51 270 276 I-treatment
( 52 53 277 278 O
infliximab 53 63 278 288 B-treatment
, 63 64 288 289 O
adalimumab 65 75 290 300 B-treatment
, 75 76 300 301 O
certolizumab 77 89 302 314 B-treatment
, 89 90 314 315 O
vedolizumab 91 102 316 327 B-treatment
, 102 103 327 328 O
natalizumab 104 115 329 340 B-treatment
within 116 122 341 347 O
8 123 124 348 349 B-upper_bound
weeks 125 130 350 355 I-upper_bound
prior 131 136 356 361 I-upper_bound
to 137 139 362 364 O
Baseline 140 148 365 373 O
or 149 151 374 376 O
ustekinumab 152 163 377 388 B-treatment
within 164 170 389 395 O
12 171 173 396 398 B-upper_bound
weeks 174 179 399 404 I-upper_bound
prior 180 185 405 410 I-upper_bound
to 186 188 411 413 O
Baseline 189 197 414 422 O
) 197 198 422 423 O

Subject 0 7 424 431 O
with 8 12 432 436 O
a 13 14 437 438 O
current 15 22 439 446 O
diagnosis 23 32 447 456 O
of 33 35 457 459 O
ulcerative 36 46 460 470 B-chronic_disease
colitis 47 54 471 478 I-chronic_disease
or 55 57 479 481 O
indeterminate 58 71 482 495 B-chronic_disease
colitis 72 79 496 503 I-chronic_disease

Subjects 0 8 504 512 O
with 9 13 513 517 O
unstable 14 22 518 526 O
doses 23 28 527 532 O
of 29 31 533 535 O
concomitant 32 43 536 547 O
Crohn 44 49 548 553 B-treatment
's 49 51 553 555 I-treatment
disease 52 59 556 563 I-treatment
therapy 60 67 564 571 I-treatment

Where 0 5 572 577 O
locally 6 13 578 585 O
permissible 14 25 586 597 O
, 25 26 597 598 O
subjects 27 35 599 607 O
16 36 38 608 610 B-lower_bound
to 39 41 611 613 O
< 42 43 614 615 O
18 44 46 616 618 B-upper_bound
years 47 52 619 624 I-upper_bound
of 53 55 625 627 O
age 56 59 628 631 B-age
who 60 63 632 635 O
meet 64 68 636 640 O
the 69 72 641 644 O
definition 73 83 645 655 O
of 84 86 656 658 O
Tanner 87 93 659 665 O
stage 94 99 666 671 O
5 100 101 672 673 O
for 102 105 674 677 O
development 106 117 678 689 O
at 118 120 690 692 O
the 121 124 693 696 O
Baseline 125 133 697 705 O
Visit 134 139 706 711 O

any 0 3 712 715 O
investigational 4 19 716 731 O
biologic 20 28 732 740 O
or 29 31 741 743 O
other 32 37 744 749 O
agent 38 43 750 755 O
or 44 46 756 758 O
procedure 47 56 759 768 O
within 57 63 769 775 O
minimally 64 73 776 785 O
35 74 76 786 788 B-upper_bound
days 77 81 789 793 I-upper_bound
or 82 84 794 796 O
5 85 86 797 798 B-upper_bound
half 87 91 799 803 I-upper_bound
- 91 92 803 804 I-upper_bound
lives 92 97 804 809 I-upper_bound
prior 98 103 810 815 I-upper_bound
to 104 106 816 818 O
Baseline 107 115 819 827 O
, 115 116 827 828 O
whichever 117 126 829 838 O
is 127 129 839 841 O
longer 130 136 842 848 O

female 0 6 849 855 B-gender

